Sequential Medicine Ltd
The purpose of this study is to investigate the effectiveness, safety and tolerability of a combination drug product (SM-1) containing diphenhydramine, zolpidem and lorazepam, in adult participants who sometimes have difficulty in falling asleep or staying asleep, but who do not have chronic insomnia. Participants will receive SM-1 or a combination of diphenhydramine and lorazepam during 2 one-night stays at a sleep center.
The purpose of this study is to evaluate the effect of a combination drug product containing 50 mg diphenhydramine, 5 mg zolpidem and 0.5 mg lorazepam on total sleep time, and to determine the contribution of zolpidem to the combination, using a 3-hour Phase Advance model of sleep challenge with 8 hours of polysomnographic (PSG) recording. This is a 2-arm, 2-period crossover trial including the 3-drug investigational product and a 2-drug comparator. The 2 arms are: investigational combination product, and a 2-drug comparator containing diphenhydramine and lorazepam but not zolpidem. Participan…
Inclusion Criteria: 1. Age 25 and 55 years 2. Body mass index (BMI) between 19 and 32 kg/m2 3. Report previous history of occasional difficulty falling asleep or staying asleep, but not currently having difficulty sleeping; 4. Regular, habitual bedtime between 21:00 and 24:00, routinely spend at least 7.5 and no more than 9.0 hours in bed nightly and a bedtime that does not vary by more than 2 hours over the course of the week. 5. Good general health 6. Females of childbearing potential must be using an acceptable method of contraception, have a negative serum pregnancy test at screening and…
diphenhydramine, zolpidem and lorazepam
diphenhydramine and lorazepam
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.